xxx xxx

Dr. xxx xxx


Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 November 2020 in Journal of Neuroscience Research
Verified
Journal Article
Open access
PDF file
PBPaola Bargagna‐Mohan
Paola Bargagna‐Mohan
GSGwendolyn Schultz
Gwendolyn Schultz
BRBruce Rheaume
Bruce Rheaume
ETEphraim F. Trakhtenberg
Ephraim F. Trakhtenberg
PRPaul Robson
Paul Robson
XXxxx xxx
xxx xxx
The cornea is the most innervated tissue in the human body. Myelinated axons upon inserting into the peripheral corneal stroma lose their myelin sheaths and continue into the central cornea wrapped by only nonmyelinating corneal Schwann cells (nm‐cSCs). This anatomical organization is believed to be important for central vision. Here we employed single‐cell RNA sequencing (scRNA‐seq), microscopy, and transgenics to characterize these nm‐cSCs of the central cornea. Using principal component analysis, uniform manifold approximation and projection, and unsupervised hierarchal cell clustering of scRNA‐seq data derived from central corneal cells of male rabbits, we successfully identified several clusters representing different corneal cell types, including a unique cell cluster representing nm‐cSCs. To confirm protein expression of cSC genes, we performed cross‐species validation, employing corneal whole‐mount immunostaining with confocal microscopy in mouse corneas. The expression of several representative proteins of nm‐cSCs were validated. As the proteolipid protein 1 (PLP1) gene was also expressed in nm‐cSCs, we explored the Plp1‐eGFP transgenic reporter mouse line to visualize cSCs. Specific and efficient eGFP expression was observed in cSCs in adult mice of different ages. Of several putative cornea‐specific SC genes identified, Dickkopf‐related protein 1 was shown to be present in nm‐cSCs. Taken together, our findings, for the first time, identify important insights and tools toward the study nm‐cSCs in isolated tissue and adult animals. We expect that our results will advance the future study of nm‐cSCs in applications of nerve repair, and provide a resource for the study of corneal sensory function.

1 January 2012 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
PBPaola Bargagna-Mohan
Paola Bargagna-Mohan
RPRiya R. Paranthan
Riya R. Paranthan
AHAdel Hamza
Adel Hamza
CZChang-Guo Zhan
Chang-Guo Zhan
DLDo-Min Lee
Do-Min Lee
XXxxx xxx
xxx xxx
The type III intermediate filaments (IFs) are essential cytoskeletal elements of mechanosignal transduction and serve critical roles in tissue repair. Mice genetically deficient for the IF protein vimentin (Vim−/−) have impaired wound healing from deficits in myofibroblast development. We report a surprising finding made in Vim−/− mice that corneas are protected from fibrosis and instead promote regenerative healing after traumatic alkali injury. This reparative phenotype in Vim−/− corneas is strikingly recapitulated by the pharmacological agent withaferin A (WFA), a small molecule that binds to vimentin and down-regulates its injury-induced expression. Attenuation of corneal fibrosis by WFA is mediated by down-regulation of ubiquitin-conjugating E3 ligase Skp2 and up-regulation of cyclin-dependent kinase inhibitors p27Kip1 and p21Cip1. In cell culture models, WFA exerts G2/M cell cycle arrest in a p27Kip1- and Skp2-dependent manner. Finally, by developing a highly sensitive imaging method to measure corneal opacity, we identify a novel role for desmin overexpression in corneal haze. We demonstrate that desmin down-regulation by WFA via targeting the conserved WFA-ligand binding site shared among type III IFs promotes further improvement of corneal transparency without affecting cyclin-dependent kinase inhibitor levels in Vim−/− mice. This dissociates a direct role for desmin in corneal cell proliferation. Taken together, our findings illuminate a previously unappreciated pathogenic role for type III IF overexpression in corneal fibrotic conditions and also validate WFA as a powerful drug lead toward anti-fibrosis therapeutic development.

8 May 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
PBPaola Bargagna-Mohan
Paola Bargagna-Mohan
SDSunil P. Deokule
Sunil P. Deokule
KTKyle Thompson
Kyle Thompson
JWJohn Wizeman
John Wizeman
CSCidambi Srinivasan
Cidambi Srinivasan
XXxxx xxx
xxx xxx
Withaferin A (WFA) is a natural product that binds to soluble forms of the type III intermediate filament (IF) vimentin. Currently, it is unknown under what pathophysiological contexts vimentin is druggable, as cytoskeltal vimentin-IFs are abundantly expressed. To investigate druggability of vimentin, we exploited rabbit Tenon's capsule fibroblast (RbTCF) cell cultures and the rabbit glaucoma filtration surgical (GFS) model of fibrosis. WFA potently caused G0/G1 cell cycle inhibition (IC50 25 nM) in RbTCFs, downregulating ubiquitin E3 ligase skp2 and inducing p27Kip1 expression. Transforming growth factor (TGF)-ß-induced myofibroblast transformation caused development of cell spheroids with numerous elongated invadopodia, which WFA blocked potently by downregulating soluble vimentin and α-smooth muscle actin (SMA) expression. In the pilot proof-of-concept study using the GFS model, subconjunctival injections of a low WFA dose reduced skp2 expression in Tenon's capsule and increased p27Kip1 expression without significant alteration to vimentin-IFs. This treatment maintains significant nanomolar WFA concentrations in anterior segment tissues that correspond to WFA's cell cycle targeting activity. A ten-fold higher WFA dose caused potent downregulation of soluble vimentin and skp2 expression, but as found in cell cultures, no further increase in p27Kip1 expression was observed. Instead, this high WFA dose potently induced vimentin-IF disruption and downregulated α-SMA expression that mimicked WFA activity in TGF-ß-treated RbTCFs that blocked cell contractile activity at submicromolar concentrations. These findings illuminate that localized WFA injection to ocular tissues exerts pharmacological control over the skp2-p27Kip1 pathway by targeting of soluble vimentin in a model of surgical fibrosis.

29 December 2022 in Journal of Neuroscience Research
Verified
Journal Article
Closed access
SPSarah I. Palko
Sarah I. Palko
NSNicholas J. Saba
Nicholas J. Saba
PBPaola Bargagna‐Mohan
Paola Bargagna‐Mohan
XXxxx xxx
xxx xxx

17 July 2015 in PLOS ONE
Verified
Journal Article
Open access
PDF file
PBPaola Bargagna-Mohan
Paola Bargagna-Mohan
LLLing Lei
Ling Lei
ATAlexis Thompson
Alexis Thompson
CSCamille Shaw
Camille Shaw
KKKousuke Kasahara
Kousuke Kasahara
XXxxx xxx
xxx xxx
Vimentin is a newly recognized target for corneal fibrosis. Using primary rabbit corneal fibroblasts and myofibroblasts we show that myofibroblasts, unlike fibroblasts, display impaired cell spreading and cell polarization, which is associated with increased levels of soluble serine-38 phosphorylated vimentin (pSer38Vim). This pSer38Vim isoform is inefficiently incorporated into growing vimentin intermediate filaments (IFs) of myofibroblasts during cell spreading, and as a result, myofibroblasts maintain higher soluble pSer38Vim levels compared to fibroblasts. Moreover, the soluble vimentin-targeting small molecule and fibrotic inhibitor withaferin A (WFA) causes a potent blockade of cell spreading selectively in myofibroblasts by targeting soluble pSer38Vim for hyperphosphorylation. WFA treatment does not induce vimentin hyperphosphorylation in fibroblasts. This hyperphosphorylated pSer38Vim species in WFA-treated myofibroblasts becomes complexed with adaptor protein filamin A (FlnA), and these complexes appear as short squiggles when displaced from focal adhesions. The extracellular-signal regulated kinase (ERK) is also phosphorylated (pERK) in response to WFA, but surprisingly, pERK does not enter the nucleus but remains bound to pSer38Vim in cytoplasmic complexes. Using a model of corneal alkali injury, we show that fibrotic corneas of wild type mice possess high levels of pERK, whereas injured corneas of vimentin-deficient (Vim KO) mice that heal with reduced fibrosis have highly reduced pERK expression. Finally, WFA treatment causes a decrease in pERK and pSer38Vim expression in healing corneas of wild type mice. Taken together, these findings identify a hereto-unappreciated role for pSer38Vim as an important determinant of myofibroblast sensitivity to WFA.

23 February 2022 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
SPSarah I. Palko
Sarah I. Palko
NSNicholas J. Saba
Nicholas J. Saba
EMElias Mullane
Elias Mullane
BNBenjamin D. Nicholas
Benjamin D. Nicholas
YNYosuke Nagasaka
Yosuke Nagasaka
XXxxx xxx
xxx xxx
Muller glia (MG) play a central role in reactive gliosis, a stress response associated with rare and common retinal degenerative diseases, including age-related macular degeneration (AMD). The posttranslational modification citrullination​ targeting glial fibrillary acidic protein (GFAP) in MG was initially discovered in a panocular chemical injury model. Here, we report in the paradigms of retinal laser injury, a genetic model of spontaneous retinal degeneration (JR5558 mice) and human wet-AMD tissues that MG citrullination is broadly conserved. After laser injury, GFAP polymers that accumulate in reactive MG are citrullinated in MG endfeet and glial cell processes. The enzyme responsible for citrullination, peptidyl arginine deiminase-4 (PAD4), localizes to endfeet and associates with GFAP polymers. Glial cell–specific PAD4 deficiency attenuates retinal hypercitrullination in injured retinas, indicating PAD4 requirement for MG citrullination. In retinas of 1-mo-old JR5558 mice, hypercitrullinated GFAP and PAD4 accumulate in MG endfeet/cell processes in a lesion-specific manner. Finally, we show that human donor maculae from patients with wet-AMD also feature the canonical endfeet localization of hypercitrullinated GFAP. Thus, we propose that endfeet are a “citrullination bunker” that initiates and sustains citrullination in retinal degeneration.